CA
NZ
UK
AU
IND
US
● SXTC slid 11.5% to $4.54 on August 19, 2026, unwinding part of a squeeze that had taken shares from roughly $4 toward $6 intraday just days earlier.
● NTHI tumbled 16.27% to $4.63 on August 19, 2026, giving back part of a rally sparked by positive Phase 2a brain-cancer trial data released on August 12.
● PFSA crashed 50.62% to $13.57 on August 19, 2026, unwinding a spike that had taken shares from about $1 in early July to the high-$20s intraday just a day earlier.
● INBS dropped 17.08% to $2.67 on August 19, 2026, despite fiscal 2026Revenuerising 38% year-over-year to $4.22 million.
● CNXU slid 10.31% to $8.96 on August 19, 2026, pushing the stock near its 52-week low of $6.85, just three months after itsNasdaqdebut.
Twist Bioscience Corporation (NASDAQ:TWST) surged after Anthropic announced on August 19, 2026 that it had selected the company as an independent evaluator to validate proteins designed by Anthropic's AI models, a role that leans on Twist's synthetic DNA and complex geneManufacturingcapabilities. The announcement reinforced …
10x Genomics, Inc. (NASDAQ:TXG) has continued climbing toward a fresh 52-week high after reporting second-quarter 2026 results in early August that toppedWall Streetexpectations. The company posted revenue of $151.0 million versus a consensus estimate near $146.7 million and an adjusted per-share loss of $0.14, …
Zoetis Inc. (NYSE:ZTS) shares rose about 3.7% to $76.68 on Thursday, August 20, 2026, continuing a bounce that began after the stock touched a fresh 52-week low of $71.41 just three trading days earlier. The rally coincided with a broader market rebound: the U.S. …
Illumina, Inc. (NASDAQ:ILMN) climbed toward a fresh 52-week high on August 19-20, 2026, a period that saw a broad rally across biotech and genomics stocks after Merck and Moderna announced positive Phase 3 melanoma vaccine trial results. Sector benchmarks including the S&P Biotech ETF …
Merck & Company, Inc. (NYSE:MRK) rallied after the company and Moderna jointly reported on August 19, 2026 that the Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival. The study combined intismeran autogene, Moderna's …
Please wait processing your request...